[
  {
    "ts": "2026-01-21T12:00:00+00:00",
    "headline": "Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer",
    "summary": "Accomplished global commercial leader with deep expertise in retina drug launches Primary architect for the industry-defining launch of EYLEA® while at Regeneron Most recently served as Chief Marketing Officer, Global Ophthalmology at Merck BEDFORD, Mass., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that David W. Robinson has agreed to join the Company a",
    "url": "https://finance.yahoo.com/news/ocular-therapeutix-appoints-david-w-120000241.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "b8a3b0c9-9287-3486-8573-27c5d5f7f721",
      "content": {
        "id": "b8a3b0c9-9287-3486-8573-27c5d5f7f721",
        "contentType": "STORY",
        "title": "Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer",
        "description": "",
        "summary": "Accomplished global commercial leader with deep expertise in retina drug launches Primary architect for the industry-defining launch of EYLEA® while at Regeneron Most recently served as Chief Marketing Officer, Global Ophthalmology at Merck BEDFORD, Mass., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that David W. Robinson has agreed to join the Company a",
        "pubDate": "2026-01-21T12:00:00Z",
        "displayTime": "2026-01-21T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/5fdec8676d63e555e3a776d7e19f838d",
          "originalWidth": 936,
          "originalHeight": 316,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xBn.knsWGj7qk6e2MloWKQ--~B/aD0zMTY7dz05MzY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/5fdec8676d63e555e3a776d7e19f838d.cf.webp",
              "width": 936,
              "height": 316,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/b06rmeZC4tY1aEgSzIGYHw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/5fdec8676d63e555e3a776d7e19f838d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ocular-therapeutix-appoints-david-w-120000241.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ocular-therapeutix-appoints-david-w-120000241.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "OCUL"
            },
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]